The term of metabolic syndrome is used to describe a combination of metabolic disorders that all together

The term of metabolic syndrome is used to describe a combination
of metabolic disorders that all together, increase the risk of
type 2 diabetes mellitus (T2DM) and cardiovascular diseases.
The components of metabolic syndrome are including the presence
of central obesity, dyslipidemia, glucose intolerance and hypertension
The worldwide prevalence of metabolic syndrome is
variable, ranging from 10% to 84%, depending on geographical origins
and composition of the studied population Metabolic
syndrome prevalence has been increased substantially in the last
two decades which should be a priority for public health It is
estimated that people with metabolic syndrome are twice as likely
to die and three times as likely to have a heart attack or stroke
compared with people without the syndrome Moreover,
compared with persons without metabolic syndrome, those with
the syndrome have an approximately 5-fold increase in diabetes
risk. However, when metabolic syndrome combines with prediabetes,
the risk is increased even more Indeed, two clinical
constructs for identifying individuals at high risk of developing
type 2 diabetes are metabolic syndrome and prediabetes. Thus,
effective treatment of these at-risk individuals is imperative for the
prevention of type 2 diabetes
To date, the intestinal microbiota has been interested in its
equivocal impact on health and is an emerging investigative field
The connection between metabolic syndrome and gut microbiota
is now acknowledged and some of the therapeutic strategies
have been proposed to improve the composition of the gut
microflora in order to promote optimal metabolic health
Current investigations suggest that manipulation of the gut
microbiota by probiotics, prebiotics, and synbiotics could be a
promising approach for the management of metabolic syndrome